Specialty preclinical CRO services

Explicyte Immuno-Oncology

We test novel drugs in validated in vitro and in vivo tumor models of cancer immunotherapies and analyze the anti-tumor immune response.

In vitro screening
In vitro screening
Phenotypic screening & in vitro profiling in cancer cells co-cultured with PBMCs
Read more
In vivo studies
In vivo studies
in vivo proof-of-concept studies in validated syngeneic mouse tumor models
Read more
Biomarker analysis
Biomarker analysis
Immune biomarkers profiling in preclinical and clinical samples.
Read more

Cancer immunotherapy Latest News

  • New In vivo syngeneic mammary fat pad mouse model Shuttle session

    In view of the success of our previous shuttle sessions, which offered the opportunity to run efficacy studies in a cost-saving manner, we are planning a new shuttle on the orthotopic (OT) 4T1 mammary fat pad mouse model, which will be held in late March....

  • In vitro immune cell activation

    We set up a specialized in vitro immune cell activation assay based on the high throughput HTRF quantitation of key cytokine (e.g. IFNg) release, to assess your candidate compounds and biologics, as single agents and/or in combination, for their immunomodulatory properties to enhance immune cell activation. In addition to this functional measurement, our assay takes advantage of the real-time live cell imaging to provide a kinetic and phenotypic monitoring of immune cell activation....

  • Combination of in vivo efficacy monitoring with intratumoral biopsy to assess new cancer therapies & decipher their MoA

    Combination of intratumoral biopsy with in vivo efficacy monitoring to assess new cancer therapies & decipher their MoA Explicyte is proud to announce the recent development and validation of our new syngeneic subcutaneously-implanted MCA-205 sarcoma tumor mouse model. ...

Explicyte immuno-oncology offers preclinical contract research services for cancer immunotherapy drug discovery. Our preclinical CRO services range from cell-based assays - for the phenotypic screening of novel immunotherapeutics and the in vitro determination of the molecular mechanism of action of new anti-cancer immune modulators - to in vivo studies, using syngeneic mouse tumor models treated with antitumor immunotherapies such as immune checkpoint inhibitors (anti CTLA-4  monoclonal antibodies, anti PD1/PDL-1 antibody  therapy and IDO/TDO inhibitors). Furthermore, we offer to explore the in vivo mechanism of action of innovative immunotherapies such as anti-cancer vaccines through the profiling of the anti-tumor immune response by flow cytometry, high-content imaging and RT-qPCR. All our drug development services for cancer immunotherapy are performed in Bordeaux, France. However, we routinely serve clients in the US, EU, UK, Germany and Switzerland.